Aclidinium bromide/formoterol
| Combination of | |
|---|---|
| Aclidinium bromide | Long-acting muscarinic antagonist |
| Formoterol | Long-acting β2 agonist |
| Clinical data | |
| Trade names | Brimica Genuair, Duaklir Genuair, Duaklir Pressair |
| AHFS/Drugs.com | Professional Drug Facts |
| License data | |
| Pregnancy category |
|
| Routes of administration | Inhalation |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| KEGG | |
Aclidinium bromide/formoterol, sold under the brand names Duaklir and Brimica, is a fixed-dose combination medication for inhalation, used in the management of chronic obstructive pulmonary disease (COPD). It consists of aclidinium bromide, a long-acting muscarinic antagonist, and formoterol, a long-acting β2 agonist.[3][4]
References
- ↑ "Duaklir Genuair 340 micrograms /12 micrograms inhalation powder - Summary of Product Characteristics (SmPC)". (emc). 9 September 2019. Retrieved 26 July 2020.
- ↑ "Duaklir Pressair- aclidinium bromide and formoterol fumarte powder, metered". DailyMed. 3 July 2020. Retrieved 28 November 2020.
- 1 2 "Duaklir Genuair EPAR". European Medicines Agency (EMA). Retrieved 26 July 2020.
- 1 2 "Brimica Genuair EPAR". European Medicines Agency (EMA). Retrieved 26 July 2020.
External links
- "Aclidinium bromide". Drug Information Portal. U.S. National Library of Medicine.
- "Formoterol fumarate". Drug Information Portal. U.S. National Library of Medicine.
Adrenergic receptor modulators | |||||
|---|---|---|---|---|---|
| α1 |
| ||||
| α2 |
| ||||
| β |
| ||||
| |||||
| mAChRs |
| ||||
|---|---|---|---|---|---|
| Precursors (and prodrugs) |
| ||||
See also: Receptor/signaling modulators • Nicotinic acetylcholine receptor modulators • Acetylcholine metabolism/transport modulators | |||||
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.